This study was designed with the aim of examining the relationship between clinicopathological characteristics and mutations in the BRAF, HRAS, KRAS, and NRAS genes with metastatic disease and RAIR development in patients with differentiated thyroid cancer. Here, KRAS is linked to differentiated thyroid carcinoma.